Beyond Type 1 Regulatory T Cells: Co-expression of LAG3 and CD49b in IL-10-Producing T Cell Lineages
Type 1 regulatory CD4 T (Tr1) cells express high levels of the immunosuppressive cytokine IL-10 but not the master transcription factor Foxp3, and can suppress inflammation and promote immune tolerance. In order to identify and obtain viable Tr1 cells for research and clinical applications, co-expre...
Saved in:
Published in | Frontiers in immunology Vol. 9; p. 2625 |
---|---|
Main Authors | , , , , |
Format | Journal Article |
Language | English |
Published |
Switzerland
Frontiers Media S.A
19.11.2018
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Type 1 regulatory CD4
T (Tr1) cells express high levels of the immunosuppressive cytokine IL-10 but not the master transcription factor Foxp3, and can suppress inflammation and promote immune tolerance. In order to identify and obtain viable Tr1 cells for research and clinical applications, co-expression of CD49b and LAG3 has been proposed as a unique surface signature for both human and mouse Tr1 cells. However, recent studies have revealed that this pattern of co-expression is dependent on the stimulating conditions and the differentiation stage of the CD4
T cells. Here, using an IL-10
/Foxp3
dual reporter transgenic murine model, we demonstrate that co-expression of CD49b and LAG3 is not restricted to the Foxp3
Tr1 cells, but is also observed in Foxp3
T regulatory (Treg) cells and CD8
T cells that produce IL-10. Our data indicate that IL-10-producing Tr1 cells, Treg cells and CD8
T cells are all capable of co-expressing LAG3 and CD49b
following differentiation under IL-10-inducing conditions, and
following pathogenic insult or infection in the pulmonary mucosa. Our findings urge caution in the use of LAG3/CD49b co-expression as sole markers to identify Tr1 cells, since it may mark IL-10-producing T cell lineages more broadly, including the Foxp3
Tr1 cells, Foxp3
Treg cells, and CD8
T cells. |
---|---|
Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 Edited by: Amit Awasthi, Translational Health Science and Technology Institute, India Reviewed by: Silvia Deaglio, Università degli Studi di Torino, Italy; Ashutosh Chaudhry, Memorial Sloan Kettering Cancer Center, United States This article was submitted to T Cell Biology, a section of the journal Frontiers in Immunology |
ISSN: | 1664-3224 1664-3224 |
DOI: | 10.3389/fimmu.2018.02625 |